Pipeline

Imbrium Therapeutics Pipeline

Our robust and diversified pipeline of investigational therapy candidates has been built to address many serious medical conditions.

Preclinical Phase I Phase II Phase III Registration
CANDIDATE
INDICATION
Tinostamustine Phase II
INDICATION: Oncology

Tinostamustine is a first-in-class, new chemical entity that combines two potentially synergistic mechanisms modes of action, alkylating activity and pan histone deacetylase inhibition (or HDAC inhibition). In early clinical studies, Tinostamustine has shown promising efficacy in patients who have exhausted treatment options (relapsed/refractory malignancies).

Sunobinop Phase I
INDICATION: IAAC1

Sunobinop is a first-in-class, new chemical entity that potently and selectively activates nociceptin/orphanin-FQ (NOP) receptors. In clinical studies, Sunobinop has shown dose-dependent, statistically significant and clinically meaningful enhancement of sleep and is also under investigation for interstitial cystitis pain and overactive bladder.

Preclinical
INDICATION: Interstitial Cystitis Pain
Preclinical
INDICATION: Overactive Bladder
IMB-150 Phase I
INDICATION: Interstitial Cystitis Pain

IMB-150 is a novel inflammation targeting formulation of a non-opioid treatment for interstitial cystitis/bladder pain syndrome. Preclinical data has demonstrated favorable pharmacokinetics for IMB-150 with a prolonged duration of action.

KL-01401* Preclinical
INDICATION: Emergency Treatment of Allergic Reactions (Anaphylaxis)

KL-01401 is a novel film formulation for the emergency treatment of Anaphylaxis Associated with Severe Allergic Reactions. KL-01401 has the potential to be a substantial improvement over existing treatments including epinephrine injection.

1IAAC = Insomnia Associated with Alcohol Cessation
*Development Collaboration

 

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the investigational agents will successfully complete clinical development or gain health authority approval.

Collaboration

Find Out More